Details
Description
Inclusion Criteria
Exclusion Criteria
Details
Title Intermediate Size Expanded Access Protocol (EAP)
CC 16-903
Hospital Main Campus
Disease Myelofibrosis
Drug Pacritinib
Description
This intermediate access protocol was designed for six patients that were enrolled onto the Persist-2 protocol and deriving benefit from Pacritnib. All patients have an unmet therapy need and have provided their oral consent that they wish to move forward with the expansion protocol. This new protocol will consist of slight modifications to the Persist-2 protocol, specifically within the category of dose modifications and dose management. Additional information regarding the treatment plan is described in the Proposed Treatment Plan section of this protocol.
